Is levomepromazine a useful drug in treatment-resistant schizophrenia?

Acta Psychiatr Scand. 1992 Mar;85(3):243-5. doi: 10.1111/j.1600-0447.1992.tb08603.x.


Levomepromazine (LMP) unexpectedly improved 16 of 23 chronic treatment-resistant schizophrenic patients who were hospitalized in most cases for at least 2 years and who manifested positive symptoms, irritability and, in many cases, restlessness, hostility, uncooperativeness, poor concentration and aggressive behavior. Improvement led to discharge in 7 (6 to a foster home), placement on a waiting list for a foster home in 4 and improved behavior and autonomy in 5 patients. Five subjects developed seizures and 1 agranulocytosis. Whether improvement with LMP is caused by unique antischizophrenic properties or by diminished liability to induce side effects such as akathisia, a formal controlled study of LMP in treatment-resistant schizophrenia is merited.

MeSH terms

  • Adult
  • Aggression / drug effects
  • Agranulocytosis / chemically induced
  • Chronic Disease
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Male
  • Methotrimeprazine / adverse effects
  • Methotrimeprazine / therapeutic use*
  • Middle Aged
  • Psychiatric Status Rating Scales
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology*
  • Social Behavior


  • Methotrimeprazine